Resverlogix Corp RVX
Trading Information
- Previous Close Price
- CA$0.08
- Day Range
- CA$0.08–0.08
- 52-Week Range
- CA$0.06–0.15
- Bid/Ask
- CA$0.07 / CA$0.08
- Shares Outstanding
- 344.29M
- Market Cap
- CA$25.82M
- Volume/Avg
- 12,000 / 30,129
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 17
- Website
- https://www.resverlogix.com
Valuation
Metric | RVX |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | RVX |
|---|---|
Quick Ratio | 0.03 |
Current Ratio | 0.04 |
Interest Coverage | −1.21 |
Quick Ratio
RVX
Profitability
Metric | RVX |
|---|---|
Return on Assets (Normalized) | −121.84% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
RVX
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|!>Hr@L | LOCK|$DsCJ | $136B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|jy<f># | LOCK|?$&F | $98B | |||
| Moderna Inc MRNA | LOCK|PPqxfw | LOCK|Khl | $80B | |||
| argenx SE ADR ARGX | LOCK|j?hVNfr | LOCK|^> | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|ckQ<!& | LOCK|kW | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|#$t^#>Y | LOCK|yBX? | $31B | |||
| Incyte Corp INCY | LOCK|@!$^%t | LOCK|GqR | $24B | |||
| BioNTech SE ADR BNTX | LOCK|RT%gsV | LOCK|wL | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|Z@MMc<M | LOCK|rLGRm | $20B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|^>lsd> | LOCK|vF | $16B |